June 2022. Volume 18. Number 2

Nirsevimab prevents respiratory syncytial virus infections in term infants, but their clinical benefit and efficiency are unclear

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al.; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022;386:837-46.
Reviewers: Ochoa Sangrador C1, Balaguer Santamaría A2, González de Dios J3.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Departamento de Pediatría. Hospital Universitari General de Catalunya. Universitat Internacional de Catalunya. Barcelona. España.
3Departamento de Pediatría. Hospital General Universitario Dr. Balmis de Alicante. ISABIAL- ISABIAL-Instituto de Investigación Sanitaria y Biomédica de Alicante. Alicante. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 12/04/2022
Acceptance date: 27/04/2022
Publication date: 04/05/2022

Abstract

Authors´ conclusions: a single injection of nirsevimab given before the respiratory syncytial virus season protected healthy late-preterm and term infants from medically attended respiratory syncytial virus-associated lower respiratory tract infection.

Reviewers´ commentary: this is a complex study well designed and executed. Their results showed the need to treat 26 infants to prevent one episode of respiratory syncytial virus -associated lower respiratory tract infection, not necessarily serious. This benefit (not observed in the other main outcome studied: hospital admission) would hardly justify its widespread indication for prevention in the low-risk population studied. Independent cost-effectiveness studies would be necessary to estimate the usefulness and efficiency of nirsevimab and establish its indications.

How to cite this article

Ochoa Sangrador C, Balaguer Santamaría A, González de Dios J. Nirsevimab previene infecciones por virus respiratorio sincitial en lactantes a término, pero no están claros su beneficio clínico ni su eficiencia. Evid Pediatr. 2022;18:17.

AVC | Critically appraised articles

Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al.; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022;386:837-46.
Reviewers: Ochoa Sangrador C1, Balaguer Santamaría A2, González de Dios J3.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Departamento de Pediatría. Hospital Universitari General de Catalunya. Universitat Internacional de Catalunya. Barcelona. España.
3Departamento de Pediatría. Hospital General Universitario Dr. Balmis de Alicante. ISABIAL- ISABIAL-Instituto de Investigación Sanitaria y Biomédica de Alicante. Alicante. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 12/04/2022
Acceptance date: 27/04/2022
Publication date: 04/05/2022

How to cite this article

Ochoa Sangrador C, Balaguer Santamaría A, González de Dios J. Nirsevimab previene infecciones por virus respiratorio sincitial en lactantes a término, pero no están claros su beneficio clínico ni su eficiencia. Evid Pediatr. 2022;18:17.

04/05/2022

Linked Comment